Eli Lilly pulls Cymbalta journal ads following FDA letter

Share this article:
The FDA has called on Eli Lilly to stop running journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail to reveal risks of the drug's use.
In a letter posted on the FDA's Web site last week, the agency said that ads are considered Cymbalta promotion even though their main panels don't mention the drug. Cymbalta, also used as an antidepressant, has risks including dementia if used with older antidepressants known as monoamine oxidase inhibitors.
It can also spur allergic reactions, the FDA said. A Lilly spokesperson told the Bloomberg news agency that the ads appeared in the fourth quarter of 2004 and first quarter of 2005 but won't appear again.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.